🔗 Share this article

The recently developed medications for gonorrhoea in decades are being described as a "huge turning point" in the effort against superbug strains of the infection, according to researchers.

A Global Health Concern

Gonorrhoea infections are increasing worldwide, with figures suggesting over 82 million infections per year. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the face of increasing worldwide cases, escalating drug resistance and the very limited therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in drug-resistant strains. The WHO has designated it as a "priority pathogen". Recent surveillance showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Secure Approval

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in mid-December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts believe that focused deployment of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in concurrent days. This drug, which is also used to treat UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization GARDP worked alongside the drug firm Innoviva to bring it to fruition.

“This approval signifies a major breakthrough in the management of multidrug-resistant gonorrhoea, which up to this point has been outpacing medical innovation.”

Research Study Data and Global Access

Based on data released by a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This establishes an equal footing with the existing first-line therapy, which involves two antibiotics. The study enrolled hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. Access to a one-pill regimen such as this is seen as a "critical tool" for managing the epidemic. This is deemed essential to alleviate the strain of the disease for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.